EMLab's KnowLine offers seven open-weight decision models for RAG, agent harnesses, and enterprise workflows, spanning dense models from 0.8B to 31B plus two MoE options. 🤖
🏆 SOTA on private decision tests: KnowLine-31B-Gen1 achieves 71.86 on Jev Decision Index 0.4.1 Full. The score combines private same-skill and new-domain tests, excluding public-suite results.
⚡ Low latency with sparse activation: KnowLine-35B-A3B-Gen1.5 activates about 3B parameters and scores 65.77 Full, with 47.1 ms median latency on the leaderboard's single RTX PRO 6000 setup.
✅ Measured probability calibration: In the 31B model's public-suite evaluation, approximately 0.9–1.0% of decisions made with at least 95% confidence were wrong. Validate thresholds on your own data.
🎯 Decisions throughout the workflow: Filter retrieved documents, check supporting evidence, select tools, route tickets, and score outputs through a Jev-compatible API supporting up to 64 questions per request.
🛠️ Adapt to your business: Continue post-training with ms-swift. The development loop uses research agents to construct and decontaminate data, train, evaluate, and retain or roll back changes based on evidence.
📜 Weights: Apache 2.0. Serving code: MIT.
Show more
Premarket movers:
Tesla and Nvidia are underperforming Magnificent 7 peers, as chip, growth and other AI-related stocks are trending lower. Meanwhile, Microsoft and Apple edge higher: Tesla (TSLA) -1.1%, Nvidia (NVDA) -1%, Alphabet (GOOGL) -0.9%, Meta Platforms (META) -0.7%, Amazon (AMZN) -0.7%, Apple (AAPL) +0.1%, Microsoft (MSFT) unchanged
Generac Holdings Inc. shares (GNRC) are up 1.4% outperforming amid weakness in many other industrial names, after two bullish nods on Wall Street.
Goldman Sachs (GS -1.5%) and Wells Fargo (WFC -1%) are buys at TD Cowen, while Morgan Stanley (MS -1.2%) is rated a hold on valuations.
Levi Strauss (LEVI) falls 3.4% after the denim retailer posted the slowest growth in its direct-to-consumer channels since late 2022.
NXP Semiconductors NV shares (NXPI) are down 3.5% after Citi downgraded the chipmaker to neutral from buy, writing that it’s becoming “increasingly selective.”
Palantir shares (PLTR) gain 2.6% as Goldman Sachs upgrades to buy from neutral as the stock has underperformed this year.
PepsiCo shares (PEP) are up 2.2% after the food and beverage company reported third-quarter core earnings per share above what analysts expected.
Shares in energy and utilities companies (CVX +1.9%, OXY +2.6%) are rising as hurricane Isaias develops in the Atlantic, with oil and gas producers shutting in wells and evacuating personnel as the storm tracks toward the Gulf Coast.
Shares of Haemonetics (HAE) rise 18% after CSL Plasma expanded its relationship with the maker of blood-processing systems.
Spotify Technology SA (SPOT) falls 0.5% as it is being started with a neutral rating and $540 price target at Piper Sandler, which writes that it is “looking for a catalyst” to get more excited about the audio-streaming company.
Wolfspeed (WOLF) jumps 14% after Department of Defense announced a $1.5b conditional loan commitment to the company.
Show more
CHOOSE YOUR FIGHTER
Warren Buffett vs Stanley Druckenmiller
Buffett stepped down as Charman of Berkshire Hathaway $BRK.B today. Druckenmiller has never had a losing year in more than 30 years.
Here are their full portfolios as of Q2 2026.
BERKSHIRE HATHAWAY
- Apple $AAPL: 22%
- American Express $AXP: 17%
- Google $GOOGL: about 12.6% across both share classes
- Coca-Cola $KO: 11%
- Bank of America $BAC: 9.2%
- Chevron $CVX: 4.7%
- Occidental $OXY: 4.3%
- Chubb $CB: 3.9%
- Moody's $MCO: 3.7%
- Kraft Heinz $KHC: 2.6%
- DaVita $DVA: 2.1%
- Delta $DAL: 1.8%
- SiriusXM $SIRI: 1.2%
- VeriSign $VRSN: 0.8%
- Kroger $KR: 0.7%
- Liberty Live $LLYVA: about 0.6% across both share classes
- Ally $ALLY: 0.4%
- Lennar $LEN: 0.4%
- New York Times $NYT: 0.4%
- Capital One $COF: 0.2%
- Louisiana-Pacific $LPX: 0.1%
- Nucor $NUE: 0.1%
- Macy's $M: 0.1%
- NVR $NVR
- Jefferies $JEF
- D.R. Horton $DHI
DUQUESNE FAMILY OFFICE
- Natera $NTRA: 17%
- Insmed $INSM: about 5.7% in shares and calls
- Taiwan Semi $TSM: 5.4%
- Brazil ETF $EWZ: about 5.1% in shares and calls
- Amazon $AMZN: about 4.6% in shares and calls
- STMicro $STM: 4.5%
- S&P 500 Equal Weight $RSP: about 3.7% in calls and shares
- Fox $FOXA: about 2.8% across both share classes
- YPF $REPYY: 2.7%
- CDW $CDW: about 2.7% in shares and calls
- BBB Foods $TBBB: 2.3%
- Google $GOOGL: 2.3%
- Seagate blockstack:native: 2.3%
- United Airlines $UAL: 2.1%
- Sea $SE: 2.0%
- NewAmsterdam Pharma $NAMS: 2.0%
- Russell 2000 ETF $IWM: 1.9% in calls
- Sandisk $SNDK: 1.5%
- Revolution Medicines $RVMD: 1.4%
- S&P 500 ETF: 1.3% in calls
- Bitdeer: 1.2%
- CRH: 1.1%
- Delta: 1.1%
- Tesla $TSLA: 1.0% in calls
- Fluor: 1.0%
- D.R. Horton: 0.9%
- Coupang: 0.9%
- AMD: 0.8%
- Palo Alto Networks: 0.8%
- Cleveland-Cliffs: 0.8%
- Hut 8: 0.7%
- Caris Life Sciences: 0.6%
- Argentina ETF: 0.6%
- Woodward: 0.5%
- Meta: 0.5% in calls
- Nuvation Bio: 0.5%
- Protagonist Therapeutics: 0.5%
- Roku: 0.5%
- Cavco: 0.5%
- ADMA Biologics: 0.4%
- Hyperliquid Strategies: 0.4%
- Rambus: 0.4%
- Rhythm Pharmaceuticals: 0.4%
- Champion Homes: 0.4%
- Daktronics: 0.4%
- PureCycle: 0.4%
- Southern Copper: 0.4%
- Linde: 0.4%
- Entegris: 0.4%
- Teva: 0.4%
- Unity: 0.4%
- Aeva: 0.4%
- Riot Platforms: 0.4%
- Qnity Electronics: 0.4%
- Equinix: 0.4%
- Lam Research: 0.4%
- Definium Therapeutics: 0.3%
- Belite Bio: 0.3%
- 10x Genomics: 0.3%
- Wabtec: 0.3%
- Eli Lilly: 0.3%
- Xenon Pharmaceuticals: 0.3%
- Olema Pharmaceuticals: 0.2%
- Repligen: 0.2%
- Rocket Companies: 0.2%
- Baidu: 0.2%
- Arm: 0.2%
- Carvana: 0.2%
- Reddit: 0.2%
- Alcoa: 0.2%
- Thermo Fisher: 0.2%
- Danaher: 0.2%
- F5: 0.2%
- Vista Energy: 0.2%
- Skeena Resources: 0.2%
- JBS: 0.1%
- Monte Rosa Therapeutics: 0.1%
- Relay Therapeutics: 0.1%
- DBV Technologies: 0.1%
- CCC Intelligent Solutions: 0.1%
- UWM Holdings: 0.1%
- Navitas Semiconductor: 0.1%
- Solstice Advanced Materials: 0.1%
- FTAI Aviation: 0.1%
- Beam Therapeutics: 0.1%
- Aurora Innovation: 0.1%
- IREN: 0.1%
- Grupo Financiero Galicia: 0.1%
- Wave Life Sciences: under 0.1%
Both own Google, Delta and D.R. Horton. Neither owns Nvidia $NVDA.
Show more
ELECTION DAY FUTURES UPDATE:
1. S&P 500: -0.9%
2. Dow Jones: -0.5%
3. Nasdaq 100: -1.9%
4. Crude Oil: -1.0%
5. Gold: +0.7%
The Nasdaq 100 is now trading at its lowest level since July 26th.
Markets are pricing-in a near-certain Democrat "sweep."
Show more
In Q2/26, $MU had the biggest share gain in the Enterprise SSD market share (Total $39.2B)
Samsung 35.0%
Micron 17.2% (up from 13.1%)
Solidigm 14.1% (up from 13.6%)
SK Hynix 10.1%
Other 10.0%
Kioxia 9.1%
Sandisk 4.4%
$SKHY $SNDK
Show more
📊
@Solana is the largest network by RWA holder count at 290,353, up 133.5% year-to-date
Below is the breakdown by asset class and market share:
1) Stocks: 234.6K (80.8%)
2) Commodities: 27.2K (9.4%)
3) U.S. Treasury Debt: 8.9K (3.1%)
4) Specialty Finance: 8.1K (2.8%)
5) Asset-Backed Credit: 5.6K (1.9%)
6) Non-US Government Debt: 4.3K (1.5%)
7) Real Estate: 1.3K (0.5%)
8) Diversified Credit: 159 (0.1%)
9) Corporate Credit: 71 (0.02%)
10) Active Strategies: 27 (0.01%)
11) Private Equity: 20 (0.01%)
12) Cryptocurrencies: 12 (0.01%)
Show more
$VKTX vs $LLY in terms of Safety and tolerability so far based on available data.
Conclusion- $VKTX 17.5 mg Is the best Commercial Dose (de-risked PH3) with best tolerability-to-efficacy ratio and is competitive with retatrutide in efficacy and best in class in safety vs retatrutide.
Data here ⬇️⬇️
Retatrutide-
Safety
TRIUMPH‑1 shows:
Nausea: 4 mg: 28.6% 9 mg: 38.4% 12 mg: 42.4%
Diarrhea: 4 mg: 25.2% 9 mg: 34.1% 12 mg: 32.0% Placebo: 13.5%
Constipation: 4 mg: 23.8% 9 mg: 25.9% 12 mg: 26.1% Placebo: 10.9%
Vomiting: 4 mg: 10.6% 9 mg: 22.8% 12 mg: 25.3% Placebo: 4.8%
Dysesthesia: 4 mg: 5.1% 9 mg: 12.3% 12 mg: 12.5% Placebo: 0.9%
Keep in mind- Skin sensitivity event is not a class-wide GLP/GIP feature, could likely be linked to this molecule.
Discontinuation due to AEs 4 mg: 4.1% 9 mg: 6.9% 12 mg: 11.3% Placebo: 4.9%
Basically, a double-digit discontinuation at 12mg dose a real risk for commercial take.
$VKTX Based on Maintenance data reported last week. My focus is primarily on $17.5mg dose
Nausea
Placebo: ~10–12%
10 mg: ~15–18%
15 mg: ~18–22%
17.5 mg: ~20–25%
20 mg: ~22–28%
22.5 mg: ~25–30%
Vomiting
Placebo: ~2–3%
10 mg: ~4–6%
15 mg: ~5–7%
17.5 mg: ~6–8%20 mg: ~7–10%
22.5 mg: ~8–12%
Diarrhea
Placebo: ~8–10%
10 mg: ~10–12%
15 mg: ~12–14%
17.5 mg: ~12–15%
20 mg: ~14–17%
22.5 mg: ~15–18%
Discontinuation Due to AEs
Placebo: ~3–4%
10 mg: ~3–4%
15 mg: ~4–5%
17.5 mg: ~4–6%
20 mg: ~5–7%
22.5 mg: ~6–8%
Key point: The 17.5 mg discontinuation rate is essentially placebo‑like safety.
Show more
Mexico’s GDP grew 0.9 percent in the third quarter of 2026, slowing from 1.4 percent in the second quarter but remaining above its 10-year average of 0.4 percent.
Show more
JAPAN’S Q2 GDP GROWS 1.4% ANNUALIZED, BEATING THE 1.1% PRELIMINARY ESTIMATE AND STRENGTHENING THE CASE FOR A BOJ RATE HIKE. || CAPITAL SPENDING FELL JUST 0.9% Q/Q, BETTER THAN INITIALLY REPORTED, WHILE MARKETS NOW ALMOST FULLY PRICE A SEPTEMBER BOJ HIKE.
Show more
Singapore Private Home Price Growth Slows to 0.9% Q/Q in Q3, Below Forecast of 1.4%